- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
- Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
- Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
- Panbela Announces Poster Presentation at American Association for Cancer Research:
- Panbela Announces Transfer to OTCQB Market
- Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
- Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
- Panbela Announces Closing of Approximately $9.0 Million Public Offering
- Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
- Panbela Announces Pricing of Approximately $9.0 Million Public Offering
More ▼
Key statistics
On Wednesday, Panbela Therapeutics Inc (PBLA:QBB) closed at 0.41, 17.14% above the 52 week low of 0.35 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.41 |
---|---|
High | 0.44 |
Low | 0.40 |
Bid | -- |
Offer | -- |
Previous close | 0.43 |
Average volume | 64.76k |
---|---|
Shares outstanding | 4.85m |
Free float | 4.85m |
P/E (TTM) | -- |
Market cap | 2.09m USD |
EPS (TTM) | -184.67 USD |
Data delayed at least 15 minutes, as of May 01 2024 20:58 BST.
More ▼